PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) produce an unrivaled durable clinical response, and first-line strategies for advanced NSCLC patients without a molecular driver have been shifted from traditional doublet chemotherapy to immunotherapy-based treatments with and without chemotherapy [3,4,5,6,7,8,9].